logo
Gujarat's active Covid tally crosses 1,200 mark; 1 death reported officially, hospitals confirm 4 more

Gujarat's active Covid tally crosses 1,200 mark; 1 death reported officially, hospitals confirm 4 more

The number of active Covid cases in Gujarat reached 1,227 on Tuesday, just a day after it crossed the 1,000 mark. Meanwhile, while the state health department has officially reported just one Covid death, at least four other patients with comorbidities have lost their lives during the latest surge in cases.
A total of 105 patients were discharged on Tuesday. Of the active cases, 23 patients have been admitted to various hospitals, while 1,204 are in home isolation.
While four women have recently died due to Covid in Ahmedabad, a man admitted to Rajkot Civil Hospital died on Tuesday, confirmed the hospital administration. The state government, however, has confirmed only one death in Ahmedabad after the fresh spate of cases.
The five deaths and co-morbidities
The 55-year-old man who died on Tuesday, had been suffering from hypertension since the last one year. There was a recent detection of diabetes. He had been admitted to Rajkot Civil Hospital after he complained of breathlessness along with fever. He was also a patient of acute leukemia (blood cancer). The patient, who was under treatment at a private hospital initially, was later transferred to AIIMS Rajkot after doctors conducted an HRCT scan. AIIMS Rajkot then referred him to Rajkot Civil Hospital, where he died on Tuesday. Notably, the man had taken all three doses of Covid vaccination.
Ahmedabad's LG Hospital has reported deaths of two Covid patients with comorbidities. One 47-year-old woman from Danilimda with hypertension was admitted on May 23. Her condition deteriorated rapidly, suffering septiscemia, leading to further complications and death on May 28. Another was an 18-year-old who had delivered a child just a week before being admitted to the hospital on May 30. She was said to have developed cardiomyopathy and died at the hospital on June 2.
Two other patients, who were admitted at GMERS Sola Civil Hospital in Ahmedabad, also lost their lives. A 20-year-old Covid patient, who was admitted on May 13, delivered a pre-term baby in the seventh month of her pregnancy on May 27, and was kept on BiPAP oxygen support. On May 30, while she tested negative for Covid, her three-day-old child tested positive. On June 3, the woman suddenly left the hospital with her child, taking Discharge Against Medical Advice (DAMA). She died at her residence later that day. This is the only Covid death to have been confirmed and reported by the state government during the recent spike in cases.
The second patient to have died at GMERS Sola Civil Hospital was a 16-year-old girl from Sabarkantha, who was admitted on June 4. Medical tests confirmed that she had tested positive for Covid-19 and Hepatitis B virus. She died during treatment on June 8.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sedentary lifestyle leads to rise in non-alcoholic fatty liver disease among young adults
Sedentary lifestyle leads to rise in non-alcoholic fatty liver disease among young adults

Time of India

time44 minutes ago

  • Time of India

Sedentary lifestyle leads to rise in non-alcoholic fatty liver disease among young adults

Bengaluru: At first glance, most people wouldn't think twice about fatigue, occasional discomfort or a slightly abnormal report during routine a check-up. However, doctors in Bengaluru say these signals are now linked to something more serious: fatty liver disease, specifically, non-alcoholic fatty liver disease (NAFLD). Since Covid-19 pandemic, city hospitals reported a 30% increase in NAFLD cases, with a noticeable surge among young adults in their 20s and 30s. Unlike traditional liver disease linked to alcohol use, this condition stems from poor lifestyle, long hours of desk work, processed food, irregular meals and physical inactivity. Dr Santhosh Kumar S C, consultant, gastroenterology at Fortis Hospital, said, "We're seeing a sharp rise in non-alcoholic fatty liver disease, with over 10 patients on average per day. The main reason: Obesity." He said NAFLD cases are being observed across socio-economic groups. A person sitting at a paan stall all day, an autorickshaw or cab driver, anyone with a sedentary lifestyle is vulnerable. There are two broad types of fatty liver - alcoholic and non-alcoholic. While alcoholic fatty liver was more common earlier, now people with no or limited alcohol use are being diagnosed due to carb-heavy diets, inactivity, and prolonged sitting, he explained. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Perdagangkan CFD Emas dengan Broker Tepercaya IC Markets Mendaftar Undo Dr Harshavardhan Rao B, head of department and consultant, medical gastroenterology, Ramaiah Memorial Hospital, said, "Fatty liver isn't just about fat, it's a warning sign for your metabolism. It's now called metabolic dysfunction-associated fatty liver disease or MAFLD because it reflects the combined impact of diabetes, hypertension, obesity, abnormal cholesterol, poor diet, lack of physical activity, and even stress. " He noted a clear shift after the pandemic. "Many switched to a sedentary work-from-home lifestyle, relied on outside food, and faced longer working hours, all of which pushed physical and mental health to the back seat. As a result, we're seeing more people diagnosed incidentally with fatty liver on routine scans." MAFLD often progresses in stages, beginning with fat accumulation, followed by inflammation, and then, in some cases, fibrosis, cirrhosis, or even cancer. Many patients show no symptoms until liver damage is already underway, highlighted Dr Rao. However, the condition is often reversible in its early stages. Changes in diet, increased physical activity, regular sleep, and health checks can prevent progression. Dr Vinay Kumar B R, hepatologist and liver transplantation specialist, Narayana Health City, said, "In Bengaluru, especially among IT professionals and those with desk jobs, we see a significant rise in both diabetes and fatty liver. It's now common to find some degree of fatty liver in two to three out of every five patients during routine scans or blood tests." Dr Balaji Gurrappa, consultant, gastroenterology, Kauvery Hospital, added, "In women, Polycystic Ovarian Disease (PCOD) and use of hormonal pills can also increase risk." BOX: Precautions Maintain healthy weight Embrace balanced diet Stay physically active Manage underlying health conditions Limit or avoid alcohol BOX: Risk factors Diabetes Hypertension Cholesterol Obesity Poor lifestyle Follow more information on Air India plane crash in Ahmedabad here . Get real-time live updates on rescue operations and check full list of passengers onboard AI 171 .

BioNtech to buy CureVac in $1.25 billion share deal to boost cancer focus
BioNtech to buy CureVac in $1.25 billion share deal to boost cancer focus

Business Standard

time3 hours ago

  • Business Standard

BioNtech to buy CureVac in $1.25 billion share deal to boost cancer focus

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments. Under the agreed deal, which pairs two former rivals in the race to develop COVID-19 vaccines, each CureVac share will be exchanged for about $5.46 in BioNTech American depositary shares, or ADS, BioNTech said. The deal further underscores BioNTech's costly long-term ambition to focus on new cancer treatments and show that its success as Pfizer's COVID-19 vaccine partner, which left its balance sheet flush with billions of euros in cash, was not a fluke. "With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy," it said. CureVac about a year ago opted to focus on oncology when it agreed to sell its remaining influenza and COVID-19 vaccine development to its alliance partner, Britain's GSK. It had previously cut jobs as it sought to move beyond its failure to develop an mRNA-based COVID vaccine during the pandemic. BioNTech last week won a major shot in the arm for its cancer drug activities when Bristol Myers Squibb agreed to pay up to $11.1 billion to jointly develop a next-generation cancer immunotherapy that could take on rival Merck & Co's best-selling drug Keytruda. The company said payment in BioNTech shares would be subject to a collar mechanism - if the 10-day volume-weighted average price of BioNTech ADS shortly before the closing of the offer exceeds $126.55, the exchange ratio would be 0.04318, and if the price is lower than $84.37, the exchange ratio would be 0.06476. CureVac shareholders are expected to own between 4% and 6% of BioNTech after the deal closes, it added.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store